Koya Ozawa1, William Packwood1, Oleg Varlamov2, Yue Qi1, Aris Xie1, Melinda D Wu1,3, Zaverio Ruggeri, Jose A López4, Jonathan R Lindner1,2. 1. Cardiovascular Division, Knight Cardiovascular Institute, Oregon Health and Science University, Portland. (K.O., W.P., Y.Q., A.X., M.D.W., J.R.L.). 2. the Division of Cardiometabolic Health, Oregon National Primate Research Center, Oregon Health and Science University, Portland. (O.V., J.R.L.). 3. Department of Hematology and Oncology, Doernbecher's Children's Hospital, Oregon Health and Science University, Portland. (M.D.W.). 4. Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA (Z.R.). Blood Works NW, Seattle, WA (J.A.L.).
Abstract
BACKGROUND: Complete mechanistic understanding of impaired microvascular reflow after myocardial infarction will likely lead to new therapies for reducing infarct size. Myocardial contrast echocardiography perfusion imaging and molecular imaging were used to evaluate the contribution of microvascular endothelial-associated VWF (von Willebrand factor) and platelet adhesion to microvascular no-reflow. METHODS AND RESULTS: Myocardial infarction was produced by transient LAD ligation in WT (wild type) mice, WT mice treated with the VWF proteolytic enzyme ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), and ADAMTS13-deficient (ADAMTS13-/-) mice. Myocardial contrast echocardiography perfusion imaging and molecular imaging of VWF and platelet GP (glycoprotein) Ibα were performed 30 minutes after ischemia-reperfusion. Infarct size was measured at 3 days. Mortality during ischemia-reperfusion incrementally increased in WT+ADAMTS13, WT, and ADAMTS13-/- mice (14%, 43%, and 63%, respectively; P<0.05). For WT mice, molecular imaging signal for platelets and VWF in the postischemic risk area was 4- to 5-fold higher ( P<0.05) compared with both the remote nonischemic regions or to sham-treated mice. Signal enhancement in the risk area was completely abolished by ADAMTS13 treatment for both platelets (12.8±3.3 versus -1.0±4.4 IU; P<0.05) and VWF (13.9±4.0 versus -1.0±3.0 IU; P<0.05). ADAMTS13-/- compared with WT mice had 2- to 3-fold higher risk area signal for platelets (33.1±8.5 IU) and VWF (30.9±1.9 IU). Microvascular reflow in the risk area incrementally decreased for WT+ADAMTS13, WT, and ADAMTS13-/- mice ( P<0.05), whereas infarct size incrementally increased ( P<0.05). CONCLUSIONS: Mechanistic information on microvascular no-reflow is possible by combining perfusion and molecular imaging. In reperfused myocardial infarction, excess endothelial-associated VWF and secondary platelet adhesion in the risk area microcirculation contribute to impaired reflow and are modifiable.
BACKGROUND:Complete mechanistic understanding of impaired microvascular reflow after myocardial infarction will likely lead to new therapies for reducing infarct size. Myocardial contrast echocardiography perfusion imaging and molecular imaging were used to evaluate the contribution of microvascular endothelial-associated VWF (von Willebrand factor) and platelet adhesion to microvascular no-reflow. METHODS AND RESULTS:Myocardial infarction was produced by transient LAD ligation in WT (wild type) mice, WT mice treated with the VWF proteolytic enzyme ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), and ADAMTS13-deficient (ADAMTS13-/-) mice. Myocardial contrast echocardiography perfusion imaging and molecular imaging of VWF and platelet GP (glycoprotein) Ibα were performed 30 minutes after ischemia-reperfusion. Infarct size was measured at 3 days. Mortality during ischemia-reperfusion incrementally increased in WT+ADAMTS13, WT, and ADAMTS13-/- mice (14%, 43%, and 63%, respectively; P<0.05). For WT mice, molecular imaging signal for platelets and VWF in the postischemic risk area was 4- to 5-fold higher ( P<0.05) compared with both the remote nonischemic regions or to sham-treated mice. Signal enhancement in the risk area was completely abolished by ADAMTS13 treatment for both platelets (12.8±3.3 versus -1.0±4.4 IU; P<0.05) and VWF (13.9±4.0 versus -1.0±3.0 IU; P<0.05). ADAMTS13-/- compared with WT mice had 2- to 3-fold higher risk area signal for platelets (33.1±8.5 IU) and VWF (30.9±1.9 IU). Microvascular reflow in the risk area incrementally decreased for WT+ADAMTS13, WT, and ADAMTS13-/- mice ( P<0.05), whereas infarct size incrementally increased ( P<0.05). CONCLUSIONS: Mechanistic information on microvascular no-reflow is possible by combining perfusion and molecular imaging. In reperfused myocardial infarction, excess endothelial-associated VWF and secondary platelet adhesion in the risk area microcirculation contribute to impaired reflow and are modifiable.
Authors: Patricia A Schumann; Jonathan P Christiansen; Rachel M Quigley; Thomas P McCreery; Robert H Sweitzer; Evan C Unger; Jonathan R Lindner; Terry O Matsunaga Journal: Invest Radiol Date: 2002-11 Impact factor: 6.016
Authors: Chad L Carr; Yue Qi; Brian Davidson; Scott Chadderdon; Ananda R Jayaweera; J Todd Belcik; Cameron Benner; Aris Xie; Jonathan R Lindner Journal: Arterioscler Thromb Vasc Biol Date: 2011-11 Impact factor: 8.311
Authors: T O Nossuli; V Lakshminarayanan; G Baumgarten; G E Taffet; C M Ballantyne; L H Michael; M L Entman Journal: Am J Physiol Heart Circ Physiol Date: 2000-04 Impact factor: 4.733
Authors: Yani Liu; Brian P Davidson; Qi Yue; Todd Belcik; Aris Xie; Yoichi Inaba; Owen J T McCarty; Garth W Tormoen; Yan Zhao; Zaverio M Ruggeri; Beat A Kaufmann; Jonathan R Lindner Journal: Circ Cardiovasc Imaging Date: 2012-12-13 Impact factor: 7.792
Authors: Simon F De Meyer; Alexander S Savchenko; Michael S Haas; Daphne Schatzberg; Michael C Carroll; Alexandra Schiviz; Barbara Dietrich; Hanspeter Rottensteiner; Friedrich Scheiflinger; Denisa D Wagner Journal: Blood Date: 2012-08-22 Impact factor: 22.113
Authors: Brian Mott; William Packwood; Aris Xie; J Todd Belcik; Ronald P Taylor; Yan Zhao; Brian P Davidson; Jonathan R Lindner Journal: JACC Cardiovasc Imaging Date: 2016-06-15
Authors: Derek J B Kleinveld; Derek D G Simons; Charlotte Dekimpe; Shannen J Deconinck; Pieter H Sloos; M Adrie W Maas; Jesper Kers; Joshua Muia; Karim Brohi; Jan Voorberg; Karen Vanhoorelbeke; Markus W Hollmann; Nicole P Juffermans Journal: Blood Adv Date: 2021-09-14
Authors: Weihui Shentu; Koya Ozawa; The Anh Nguyen; Melinda D Wu; William Packwood; Aris Xie; Matthew A Muller; Eran Brown; Matthew W Hagen; José A López; Jonathan R Lindner Journal: J Am Soc Echocardiogr Date: 2020-11-27 Impact factor: 5.251